Perceptive Advisors LLC Boosts Stake in enGene Holdings Inc. $ENGN

Perceptive Advisors LLC lifted its position in shares of enGene Holdings Inc. (NASDAQ:ENGN) by 179.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,869,076 shares of the company’s stock after acquiring an additional 3,771,840 shares during the quarter. Perceptive Advisors LLC owned 8.76% of enGene worth $52,998,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Privium Fund Management B.V. purchased a new stake in shares of enGene during the 4th quarter worth about $3,179,000. Braidwell LP purchased a new stake in shares of enGene during the 3rd quarter worth about $15,479,000. Omega Fund Management LLC lifted its holdings in enGene by 66.5% during the fourth quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after purchasing an additional 350,000 shares in the last quarter. Eventide Asset Management LLC purchased a new position in enGene during the fourth quarter valued at $8,578,000. Finally, Cormorant Asset Management LP lifted its holdings in enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ENGN has been the topic of several recent analyst reports. Oppenheimer downgraded shares of enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Morgan Stanley downgraded shares of enGene to an “underweight” rating and set a $3.00 price objective on the stock. in a report on Thursday. WBB Securities initiated coverage on shares of enGene in a report on Monday, April 13th. They set a “buy” rating and a $21.50 price objective on the stock. Leerink Partners downgraded shares of enGene from an “outperform” rating to a “market perform” rating and set a $2.00 price objective on the stock. in a report on Friday, May 8th. Finally, UBS Group decreased their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $11.05.

enGene Stock Performance

ENGN opened at $1.74 on Thursday. The company has a quick ratio of 11.75, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. The company has a market cap of $116.56 million, a price-to-earnings ratio of -0.80 and a beta of -0.30. enGene Holdings Inc. has a 52-week low of $1.40 and a 52-week high of $12.25. The firm’s fifty day simple moving average is $4.10 and its two-hundred day simple moving average is $7.10.

enGene (NASDAQ:ENGN) last issued its earnings results on Monday, June 15th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.91. During the same quarter last year, the firm earned $0.51 earnings per share. Equities analysts anticipate that enGene Holdings Inc. will post -1.97 earnings per share for the current fiscal year.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.